NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by alpha-glucosidase inhibitor in addition to diet and exercise therapies
Date of first enrollment	23/08/2006
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : SMP-508 (repaglinide) INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral

Outcome(s)

Primary Outcome	Efficacy: postprandial blood glucose, HbA1c etc
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	<Inclusion criteria> Patients with type 2 diabetes mellitus who satisfy the following inclusion criteria -Patients who are taking alpha-glucosidase inhibitor in addition to diet and exercise therapies -Patients whose HbA1c levels are 6.5%<=HbA1c<=9.0%, and are stable over 4 weeks -Patients aged 20 or older -Outpatients etc. <Exclusion criteria> -Patients with hepatic dysfunction -Patients with renal dysfunction -Patients with cardiac diseases or severe hypertension etc.
Exclude criteria